Fluidigm Corporation (FLDM) : Zacks Investment Research ranks Fluidigm Corporation (FLDM) as 3, which is a Hold recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 4 research analysts is 2, which indicates as a Buy.
Fluidigm Corporation (FLDM) : 4 Wall Street analysts covering Fluidigm Corporation (FLDM) believe that the average level the stock could reach for the short term is $11.63. The maximum price target given is $14 and the minimum target for short term is around $10, hence the standard deviation is calculated at $1.89.
For the current week, the company shares have a recommendation consensus of Buy. Fluidigm Corporation (NASDAQ:FLDM): The stock opened at $9.05 on Thursday but the bulls could not build on the opening and the stock topped out at $9.09 for the day. The stock traded down to $8.82 during the day, due to lack of any buying support eventually closed down at $8.88 with a loss of -1.22% for the day. The stock had closed at $8.99 on the previous day. The total traded volume was 150,727 shares.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director officer (PRESIDENT & CEO) of Fluidigm Corp, Worthington Gajus Vincent had sold 6,000 shares worth of $69,000 in a transaction dated November 3, 2015. In this transaction, 6,000 shares were sold at $11.5 per share.
Fluidigm Corporation creates, manufactures and market technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Companys core microfluidics and mass cytometry technologies. The Company also offers instruments and consumables to academic institutions, clinical laboratories, pharmaceutical, biotechnology and agricultural biotechnology (Ag-Bio) companies. The Company sells technologies and life-science tools, including analytical and preparatory systems for genomic and proteomic analysis, and consumables, including Integrated Fluidic Circuits (IFCs), assays, and reagents. The Companys products include C1 Single-Cell Auto Prep System; Access Array System; Biomark HD System; EP1 System; CyTOF 2 System; IFCs include C1 IFCs; Access Array IFC; Dynamic Array IFCs; Digital Array IFCs; Flex Six IFC; Access Array Target-Specific Primers, and Maxpar Reagents, among others.